Breaking News Instant updates and real-time market news.

PHAT

Phathom Pharmaceuticals

$25.80

0.8 (3.20%)

, CELG

Bought by BMY

$0.00

(0.00%)

08:39
12/02/19
12/02
08:39
12/02/19
08:39

Phathom Pharmaceuticals CEO David Socks moves to CFO, Terrie Curran to succeed

Phathom Pharmaceuticals (PHAT) announced multiple executive appointments. Terrie Curran, former president of the global inflammation and immunology franchise at Celgene (CELG), now joins Phathom as CEO. Founding CEO David Socks transitions to interim CFO and remains a member of the board. In addition to Curran, also joining the Phathom leadership team are Eckhard Leifke as CMO, Joseph Hand, as chief administrative officer and Larry Miller as general counsel. Phathom also announced that Asit Parikh has replaced Chris Slavinsky on the company's board. Leifke joins Phathom from Omeros (OMER) where he served as CMO. Hand joins Phathom from Celgene, where he most recently served as executive VP, global human resources and corporate services and a member of its executive committee. Miller joins Phathom as general counsel from Cyclerion Therapeutics where he served as general counsel and secretary.

PHAT

Phathom Pharmaceuticals

$25.80

0.8 (3.20%)

CELG

Bought by BMY

$0.00

(0.00%)

OMER

Omeros

$14.76

0.38 (2.64%)

  • 04

    Dec

  • 07

    Dec

  • 25

    Mar

  • 04

    Apr

PHAT Phathom Pharmaceuticals
$25.80

0.8 (3.20%)

11/19/19
EVER
11/19/19
INITIATION
EVER
Outperform
Phathom Pharmaceuticals initiated with an Outperform at Evercore ISI
Evercore ISI analyst Umer Raffat initiated coverage of Phathom Pharmaceuticals with an Outperform rating.
11/19/19
11/19/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Shake Shack (SHAK) initiated with a Neutral at Baird. 2. L3Harris Technologies (LHX) initiated with an Overweight at Alembic Global. 3. Phathom Pharmaceuticals (PHAT) was initiated with a Buy at Jefferies and Needham and a Neutral at Goldman Sachs. 4. Cabaletta Bio (CABA) initiated with an Outperform at Cowen and Evercore ISI as well as an Overweight at Morgan Stanley. 5. Agenus (AGEN) resumed with a Buy at B. Riley FBR. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
11/19/19
NEED
11/19/19
INITIATION
Target $40
NEED
Buy
Phathom Pharmaceuticals initiated with a Buy at Needham
Needham analyst Alan Carr initiated coverage of Phathom Pharmaceuticals (PHAT) with a Buy rating and $40 price target. The analyst is positive on the company's development of vonoprazan, a "novel oral potassium-competitive acid blocker for the treatment of Erosive Esophagitis and H. pylori infection", noting that its 2015 launch by Takeda (TAK) in Japan has demonstrated benefits over standard of care proton pump inhibitors in both indications. Having licensed the rights from Takeda, the analyst adds that the company's initiated Phase 3 trials in Erosive Esophagitis and H. pylori infection for registration in the U.S., Canada, and Europe, projecting a U.S. launch in 2022 and and U.S. peak sales of $1.9B-$2.0B in 2032.
11/19/19
JEFF
11/19/19
INITIATION
Target $32
JEFF
Buy
Phathom Pharmaceuticals initiated with a Buy at Jefferies
Jefferies analyst David Steinberg initiated coverage of Phathom Pharmaceuticals with a Buy rating and $32 price target. He said the company's lead asset, vonoprazan, is "unusually de-risked" after having already achieved commercial success in Japan and he believes the drug could achieve peak sales in the U.S. of over $1B, assuming successful Phase 3 readouts in 2021.
CELG Bought by BMY
$0.00

(0.00%)

11/01/19
BARD
11/01/19
DOWNGRADE
Target $101
BARD
Neutral
Celgene downgraded to Neutral at Baird
As reported previously, Baird analyst Brian Skorney downgraded Celgene to Neutral from Outperform. The analyst cited its recent upward move and doesn't see any reason for holding the shares ahead of ASH where any hair out the TRANSCEND data could put the entire CVR at risk. Skorney maintained his $101 price target on Celgene shares.
11/01/19
BARD
11/01/19
DOWNGRADE
Target $101
BARD
Neutral
Celgene downgraded d to Neutral from Outperform at Baird
Baird analyst Brian Skorney downgraded d to Neutral from Outperform with a $101 price target.
09/23/19
GUGG
09/23/19
UPGRADE
Target $55
GUGG
Buy
Agios Pharmaceuticals upgraded to Buy following selloff at Guggenheim
Guggenheim analyst Michael Schmidt upgraded Agios Pharmaceuticals (AGIO) to Buy from Neutral following a 20% year-to-date selloff in the shares, stating that the current valuation reflects no value beyond Tibsovo and Idhifa. Even with more conservative estimates, he believes Tibsovo alone is worth $35 per share and Idhifa royalties from Celgene (CELG) are worth $4, giving the stock a one-year "floor valuation" of $39 per share. Meanwhile, feedback from doctors highlights a moderate but "real" commercial opportunity in PKD for Mitapivat, said Schmidt, who set a $55 price target on Agios shares.
11/01/19
STPT
11/01/19
DOWNGRADE
STPT
Hold
Celgene downgraded to Hold from Buy at Standpoint Research
Standpoint Research analyst Ronnie Moas downgraded Celgene to Hold from Buy.
OMER Omeros
$14.76

0.38 (2.64%)

11/05/19
HCWC
11/05/19
NO CHANGE
Target $35
HCWC
Buy
Omeros recent selloff appears unwarranted, says H.C. Wainwright
H.C. Wainwright analyst Raghuram Selvaraju believes the recent selloff in shares of Omeros appears unwarranted. Despite the favorable Omidira data, Omeros shares were down over 16% in market trading yesterday, Selvaraju tells investors in a research note. He believes the downside action was driven by "disappointment" that pass-through reimbursement status for Omidira was not formally extended by the Centers for Medicare and Medicaid Services. However, the pullback "appears to have been overdone and premature," says Selvaraju, who reiterates a Buy rating on Omeros with a $35 price target.
05/06/19
CANT
05/06/19
INITIATION
CANT
Overweight
Omeros initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald initiated Omeros with an Outperform and $26 price target.
05/06/19
05/06/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. PagerDuty (PD) initiated with an Overweight at Piper Jaffray, with a Neutral at BTIG, with an Outperform at William Blair, with an Overweight at JPMorgan, with a Sector Weight at KeyBanc, with an Equal Weight at Morgan Stanley and with a Sector Perform at RBC Capital. 2. Tufin (TUFN) initiated with a Buy at Jefferies, with an Overweight at Piper Jaffray, with a Market Perform at William Blair, with a Hold at Stifel, with an Outperform at Oppenheimer, with an Overweight at JPMorgan and with an Overweight at Barclay. 3. Aclaris Therapeutics (ACRS) initiated with an Outperform at SVB Leerink. 4. Jumia Technologies (JMIA) initiated with a Neutral at Citi and with a Sector Perform at RBC Capital. 5. Omeros (OMER) initiated with an Overweight at Cantor Fitzgerald. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
05/06/19
CANT
05/06/19
INITIATION
Target $26
CANT
Overweight
Omeros initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald analyst Brandon Folkes initiated coverage of Omeros with an Overweight rating and $26 price target. The analyst believes investors can be rewarded from current levels through the company's pipeline alone. As such, the risk/reward is to the upside, "creating a compelling investment opportunity," Folkes tells investors in a research note.

TODAY'S FREE FLY STORIES

21:55
12/09/19
12/09
21:55
12/09/19
21:55
General news
Treasury Market Summary »

Treasury Market Summary:…

AUPH

Aurinia Pharmaceuticals

$15.76

0.31 (2.01%)

21:03
12/09/19
12/09
21:03
12/09/19
21:03
Syndicate
Aurinia Pharmaceuticals 11.1M share Secondary priced at $15.00 »

The deal size was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

GDI

Gardner Denver

$33.90

-0.19 (-0.56%)

20:08
12/09/19
12/09
20:08
12/09/19
20:08
Downgrade
Gardner Denver rating change at BTIG »

Gardner Denver downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GDI

Gardner Denver

$33.90

-0.19 (-0.56%)

19:56
12/09/19
12/09
19:56
12/09/19
19:56
Downgrade
Gardner Denver rating change at BTIG »

Gardner Denver downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DTCWY

Deutsche Wohnen

$0.00

(0.00%)

19:50
12/09/19
12/09
19:50
12/09/19
19:50
Downgrade
Deutsche Wohnen rating change at Goldman Sachs »

Deutsche Wohnen…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SEGXF

Segro

$0.00

(0.00%)

19:49
12/09/19
12/09
19:49
12/09/19
19:49
Downgrade
Segro rating change at Goldman Sachs »

Segro downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BORR

Borr Drilling

$6.60

0.46 (7.49%)

19:30
12/09/19
12/09
19:30
12/09/19
19:30
Initiation
Borr Drilling initiated at Goldman Sachs »

Borr Drilling initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INSG

Inseego

$6.89

-0.05 (-0.72%)

19:26
12/09/19
12/09
19:26
12/09/19
19:26
Syndicate
Breaking Syndicate news story on Inseego »

Inseego files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FTSV

Forty Seven

$30.44

16.04 (111.39%)

19:25
12/09/19
12/09
19:25
12/09/19
19:25
Conference/Events
Forty Seven to hold an investor event »

Investor Event will be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 09

    Dec

ARQL

ArQule

$19.71

10.035 (103.77%)

19:25
12/09/19
12/09
19:25
12/09/19
19:25
Conference/Events
ArQule »

Management holds an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 09

    Dec

  • 09

    Dec

  • 09

    Dec

XNCR

Xencor

$41.41

0.39 (0.95%)

19:25
12/09/19
12/09
19:25
12/09/19
19:25
Conference/Events
Xencor to host analyst & investor meeting »

Analyst & Investor…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 09

    Dec

ABR

Arbor Realty

$14.78

(0.00%)

19:20
12/09/19
12/09
19:20
12/09/19
19:20
Syndicate
Arbor Realty 6.5M share Spot Secondary priced at $14.14 »

The deal size was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

STRM

Streamline Health

$1.25

-0.04 (-3.10%)

18:59
12/09/19
12/09
18:59
12/09/19
18:59
Hot Stocks
Streamline Health delaying Q3 results to resolve amortization charge »

Streamline Health…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NLOK

NortonLifeLock

$25.43

-0.02 (-0.08%)

, INTC

Intel

$56.52

-0.28 (-0.49%)

18:55
12/09/19
12/09
18:55
12/09/19
18:55
Periodicals
McAfee weighs combination with NortonLifeLock, WSJ reports »

NortonLifeLock (NLOK) has…

NLOK

NortonLifeLock

$25.43

-0.02 (-0.08%)

INTC

Intel

$56.52

-0.28 (-0.49%)

AVGO

Broadcom

$314.49

-1.68 (-0.53%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 12

    Dec

  • 19

    Dec

  • 23

    Jan

TGTX

TG Therapeutics

$9.28

2.17 (30.52%)

18:55
12/09/19
12/09
18:55
12/09/19
18:55
Conference/Events
TG Therapeutics to host investor & analyst meeting »

Investor & Analyst…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

NTNX

Nutanix

$33.87

-0.725 (-2.10%)

18:41
12/09/19
12/09
18:41
12/09/19
18:41
Hot Stocks
Nutanix CEO: We are transitioning to a subscription-based model »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 13

    Dec

  • 16

    Dec

SFIX

Stitch Fix

$25.17

1.04 (4.31%)

, MDB

MongoDB

$131.03

-0.19 (-0.14%)

18:33
12/09/19
12/09
18:33
12/09/19
18:33
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS: Stitch…

SFIX

Stitch Fix

$25.17

1.04 (4.31%)

MDB

MongoDB

$131.03

-0.19 (-0.14%)

PHR

Phreesia

$29.01

-0.09 (-0.31%)

CDMO

Avid Bioservices

$5.85

0.05 (0.86%)

MTN

Vail Resorts

$231.30

-1.43 (-0.61%)

TOL

Toll Brothers

$41.40

0.515 (1.26%)

EQ

Equillium

$4.00

-0.03 (-0.74%)

SUPN

Supernus

$22.69

-0.145 (-0.63%)

A

Agilent

$81.68

-0.545 (-0.66%)

HEPA

Hepion Pharmaceuticals

$5.61

0.4 (7.68%)

ROAD

Construction Partners

$20.56

0.66 (3.32%)

CASY

Casey's General Stores

$175.33

-0.47 (-0.27%)

CHWY

Chewy

$24.17

-0.76 (-3.05%)

LVGO

Livongo Health

$27.40

-0.6 (-2.14%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 09

    Dec

  • 09

    Dec

  • 09

    Dec

  • 09

    Dec

  • 09

    Dec

  • 10

    Dec

  • 10

    Dec

  • 10

    Dec

  • 10

    Dec

  • 11

    Dec

  • 12

    Dec

  • 18

    Dec

  • 19

    Dec

BLUE

Bluebird Bio

$76.72

-2.79 (-3.51%)

, BMY

Bristol-Myers

$61.32

1.38 (2.30%)

18:24
12/09/19
12/09
18:24
12/09/19
18:24
Hot Stocks
Bluebird Bio, Bristol-Myers present update on Phase 1 study of bb21217 »

Bluebird bio (BLUE) and…

BLUE

Bluebird Bio

$76.72

-2.79 (-3.51%)

BMY

Bristol-Myers

$61.32

1.38 (2.30%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 11

    Dec

BA

Boeing

$351.25

-2.74 (-0.77%)

18:22
12/09/19
12/09
18:22
12/09/19
18:22
Periodicals
Former Boeing employee Pierson to testify at U.S. House hearing, Reuters says »

An ex-Boeing employee who…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

OXY

Occidental Petroleum

$37.34

-0.07 (-0.19%)

18:21
12/09/19
12/09
18:21
12/09/19
18:21
Hot Stocks
Occidental Petroleum director buys 12.9K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

OXY

Occidental Petroleum

$37.34

-0.07 (-0.19%)

18:14
12/09/19
12/09
18:14
12/09/19
18:14
Hot Stocks
Occidental Petroleum director buys 10K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

EDIT

Editas Medicine

$30.34

-0.6 (-1.94%)

18:02
12/09/19
12/09
18:02
12/09/19
18:02
Hot Stocks
Editas Medicine announces in vivo proof-of-concept data for EDIT-301 »

Editas Medicine announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MSB

Mesabi Trust

$23.93

0.71 (3.06%)

, CLF

Cleveland-Cliffs

$8.52

0.38 (4.67%)

17:56
12/09/19
12/09
17:56
12/09/19
17:56
Hot Stocks
Mesabi Trust initiates arbitration against Northshore Mining, Cleveland-Cliffs »

The Trustees of Mesabi…

MSB

Mesabi Trust

$23.93

0.71 (3.06%)

CLF

Cleveland-Cliffs

$8.52

0.38 (4.67%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FFBC

First Financial Bancorp

$24.67

0.12 (0.49%)

17:51
12/09/19
12/09
17:51
12/09/19
17:51
Hot Stocks
First Financial Bancorp chairman Davis sells 25,000 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GPRE

Green Plains

$14.26

-0.49 (-3.32%)

17:47
12/09/19
12/09
17:47
12/09/19
17:47
Hot Stocks
Green Plains CEO Todd Becker sold over 607K in company shares »

Green Plains CEO Todd…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.